Search | Clinical Trials Finder

Conditions: Healthy Volunteer
Interventions: GDC-0310, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK2330672, Placebo, Sitagliptin, Metformin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 64 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more

Conditions: Suicide, Suicide Threat, Depression Severe
Interventions: Ketamine Hydrochloride, Normal saline; Drug
Lead sponsor: Naval Medical Center Camp Lejeune; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Marine Corps Base Camp Lejeune, North Carolina

Conditions: Hyperhidrosis
Interventions: Botulinum Type B, Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: NMO Spectrum Disorder, Spasticity, Muscle
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Michael, Levy M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Caloric Restriction, Exercise, Sleep
Interventions: Testosterone Undecanoate, Sesame Oil; Drug
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Autonomic Nervous System, Baroreflex, Stress, Physiological
Interventions: Cosyntropin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma
Interventions: Optune® device, Temozolomide, Pembrolizumab, Placebo; Device · Drug
Lead sponsor: NovoCure GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more

Conditions: Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions: AP-SA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more

Conditions: Major Depressive Disorder
Interventions: GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more

Conditions: Healthy Volunteer
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Influenza
Interventions: CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free, CSL Trivalent Inactivated Influenza Vaccine with Thimerosal, Placebo with Thimerosal; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 1,359 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 10
States / cities: Stanford, California • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
Interventions: Crofelemer Powder for Oral Solution, Placebo Powder for Oral Solution; Drug
Lead sponsor: Napo Pharmaceuticals, Inc.; Industry
Eligibility: Up to 17 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more

Conditions: Cystic Fibrosis
Interventions: QR-010, Placebo; Drug
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Chicago, Illinois + 8 more

Conditions: Vitamin D Deficiency
Interventions: Placebo, 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth, Usual Care; Dietary Supplement · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 24 Hours to 96 Hours
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colonoscopy, Adjunct Anesthesia Medication
Interventions: Diphenhydramine, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 64 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Glyocopyrrolate Inhalation Solution administered by Magnair, Placebo administered by Magnair; Combination Product · Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Glabellar Lines
Interventions: Placebo, AGN-151586; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Birmingham, Alabama • Encino, California • Los Angeles, California + 15 more

Conditions: Cytomegalovirus Anterior Uveitis
Interventions: Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet, Topical placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatitis C, Chronic
Interventions: BI201335, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • New York, New York + 1 more

Conditions: HIV Infections
Interventions: VSV-Indiana HIV gag vaccine, Placebo injection (normal saline); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 4
States / cities: San Francisco, California • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more

Conditions: Knee Osteoarthritis
Interventions: Fasitibant- low dose, Fasitibant- intermediate dose, Fasitibant- high dose, Placebo comparator; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 9
States / cities: Tucson, Arizona • Englewood, Colorado • DeLand, Florida + 5 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department

Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

Stress and the Nervous System

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants

Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID)

Phase 3 IGIV, 10% in Alzheimer´s Disease

Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients

ViDES Trial (Vitamin D Extra Supplementation)

Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids

A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

Evaluating the Safety of and Immune Response to the VSV-Indiana HIV Vaccine in Healthy, HIV-Uninfected Adults

Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)